RECCE PHARMACEUTICALS LTD — Board/Management Information 2017

Jan 22, 2017

ASX Announcement

==> picture [132 x 118] intentionally omitted <==

21 January 2017

Director Resignation

Dominic Barnes has notified the Company of his resignation as a director with immediate effect. Dominic joined the Board in May 2016.

We thank him for his contribution during his time as a Director and wish him well with his future endeavours.

Peter Williams

CFO & Company Secretary

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams CFO & Company Secretary Recce Ltd Tel: (08) 9253 9800

Media (Australia) Andrew Geddes CityPR Tel: (02) 9267 4511

Media (International) Sue Charles/Daniel Gooch Instinctif Partners Tel: +44 (0)20 7866 7905 E: recce@instinctif.com

==> picture [595 x 73] intentionally omitted <==

About Recce Ltd

Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer antibiotics. The RECCE[®] antibiotics have been synthesized by an extremely economic method. RECCE[®] antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE[®] 327.

The discovery of RECCE[®] 327’s capabilities against cancer and viruses (as well as bacteriasuperbugs) has greatly increased the value of the Company’s technology, especially in view of the synergism between antibiotic/anti-cancer properties and anti-viral/anti-cancer properties.

Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies, and potential financial returns, from manufacture and distribution of its products in about 80% of the world’s pharmaceutical markets for antibiotics.

To receive the latest information on Recce - Subscribe here

==> picture [595 x 74] intentionally omitted <==